77386
2-Bromo-1-ethyl-pyridinium tetrafluoroborate
≥97.0% (T)
Synonym(s):
BEP
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C7H9BBrF4N
CAS Number:
Molecular Weight:
273.86
UNSPSC Code:
12352005
NACRES:
NA.22
PubChem Substance ID:
EC Number:
212-900-2
Beilstein/REAXYS Number:
4059265
MDL number:
Product Name
2-Bromo-1-ethyl-pyridinium tetrafluoroborate, ≥97.0% (T)
InChI key
YJDXVQLBIAJTHP-UHFFFAOYSA-N
InChI
1S/C7H9BrN.BF4/c1-2-9-6-4-3-5-7(9)8;2-1(3,4)5/h3-6H,2H2,1H3;/q+1;-1
SMILES string
F[B-](F)(F)F.CC[n+]1ccccc1Br
assay
≥97.0% (T)
form
crystals
reaction suitability
reaction type: Coupling Reactions
mp
103-107 °C
application(s)
peptide synthesis
functional group
bromo
Quality Level
Application
2-Bromo-1-ethyl-pyridinium tetrafluoroborate can be used as a coupling reagent for:
- The synthesis of N-methylated peptides in solution and solid phase.
- The synthesis of cyclosporin A fragment and dolastatin 15 pentapeptide moiety.
General description
2-Bromo-1-ethyl-pyridinium tetrafluoroborate is a coupling reagent employed in the synthesis of amides and esters through amidation and esterification reactions, respectively. It is generally prepared by the reaction of triethyloxonium tetrafluoroborate with 2?bromo pyridine.
Other Notes
Coupling reagent for peptide synthesis; less racemization and faster reaction than with other reagents;e.g. BOP, PyBrOP, PyClU, BTFFH, CMBI
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Benjamin J Burwitz et al.
Nature communications, 8(1), 2146-2146 (2017-12-17)
Hepatitis B virus (HBV) is a major global health concern, and the development of curative therapeutics is urgently needed. Such efforts are impeded by the lack of a physiologically relevant, pre-clinical animal model of HBV infection. Here, we report that
Julien Lupo et al.
AIDS (London, England), 33(6), 993-1000 (2019-04-05)
Epstein-Barr virus (EBV) has been implicated in lymphomagenesis of HIV-related classical Hodgkin lymphoma (HIV-cHL). The utility of EBV molecular and serological biomarkers has scarcely been examined in HIV-cHL in the recent combined antiretroviral therapy (cART) era. We evaluated EBV DNA
Ya-Ling Chou et al.
Journal of the Chinese Medical Association : JCMA, 82(6), 510-514 (2019-06-11)
Congenital TORCH (toxoplasmosis, other viruses [varicella-zoster virus, VZV, etc.], rubella, cytomegalovirus [CMV], Herpes simplex virus [HSV]) infections are major causes of prenatal, perinatal, and postnatal morbidity and mortality. Although treatment or prevention strategies are available for these pathogens, all drugs
Benjamin Gille et al.
SLAS technology, 23(2), 188-197 (2018-01-19)
The lack of (inter-)laboratory standardization has hampered the application of universal cutoff values for Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers and their transfer to general clinical practice. The automation of the AD biomarker immunoassays is suggested to generate more
K Clint Cary et al.
The Journal of urology, 193(2), 507-512 (2014-09-26)
Induction chemotherapy for International Germ Cell Cancer Collaborative Group (IGCCCG) good risk metastatic testicular cancer includes 3 cycles of bleomycin, etoposide and cisplatin (BEP x3) or 4 cycles of etoposide and cisplatin (EP x4). We examine differences in active cancer
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service